close

Enter

Log in using OpenID

Lysosomal Acid Lipase Deficiency Treatment Market, by Therapy Type, Drug Type, Disease Indication 2025

embed
Lysosomal acid lipase (LAL) deficiency is a rare inherited condition in which the body is not able to produce enough lysosomal acid lipase (LAL) enzyme, which is an important enzyme for breakdown of fatty materials namely cholesteryl esters and trig
LYSOSOMAL ACID LIPASE
DEFICIENCY TREATMENT MARKET
Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2017– 2025
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Overview
Lysosomal acid lipase (LAL) deficiency is a rare inherited condition in which the body is not able
to produce enough lysosomal acid lipase (LAL) enzyme, which is an important enzyme for
breakdown of fatty materials namely cholesteryl esters and triglycerides. This results in building
up of a large amount of fatty material in body organs, which include spleen, liver, and gut. The
deficiency of LAL causes two autosomal recessive disorders, Wolman disease (WD) and
Cholesteryl Ester Storage Disease (CESD). LAL deficiency is caused due to the genetic mutation in
LIPA gene, which results in decrease or loss of Lysosomal Acid Lipase (LAL) enzyme.
Request to download and view Sample Report:
https://www.coherentmarketinsights.com/insight/request-sample/904
FDA approval of innovative drugs is expected to fuel the growth of Lysosomal Acid Lipase (LAL)
Deficiency Treatment Market
The approval of innovative drugs by Food and Drug Administration (FDA) is expected to augment
the growth of market. In 2015 the U.S. Food and Drug Administration (FDA) approved Alexion
Pharmaceutical’s Kanuma(sebelipase alfa), an innovative enzyme replacement therapy (ERT).
Kanuma is first approved therapy that treats the underlying cause of the disease. It is the only
therapy for the treatment of LAL deficiency. As it is the only available therapy in market, kanuma
is expected to have a significant market growth in the near future. According to the National
Institute for Health and Care Excellence (NICE) 2016, around 50% of patients suffering from
lysosomal acid lipase (LAL) deficiency have chances of liver complications, which includes
cirrhosis or fibrosis and liver transplant
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Taxonomy
The global Lysosomal Acid Lipase (LAL) deficiency treatment market is segmented on the basis of
disease type, treatment type, and end user.
On the basis of disease type, the Lysosomal Acid Lipase (LAL) deficiency treatment market is
segmented into:
• Wolman Disease
• Cholesteryl Ester Storage Disease (CESD)
On the basis of treatment type, the Lysosomal Acid Lipase (LAL) deficiency treatment market is
segmented into:
• Liver Transplant
• Hematopoietic Stem Cell Transplant
On the basis of end users, the Lysosomal Acid Lipase (LAL) deficiency treatment market is segmented
into:
• Hospital
• Clinics
Request a Customization:
https://www.coherentmarketinsights.com/insight/request-customization/904
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
North America is expected to dominate market due to rapid novel innovations
Global market for the Lysosomal Acid Lipase (LAL) deficiency treatment market by Coherent
Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle
East, and Africa. North America is expected to dominate the lysosomal acid lipase (LAL)
deficiency treatment market attributed to rapid novel innovations, drug development, and
research. In 2015, FDA approved genetically modified organisms (GMO) chickens, for the
production of a recombinant human lysosomal acid lipase (LAL) protein in their eggs for the
treatment of lysosomal acid lipase (LAL) deficiency among Americans. Europe is expected to be
the second largest region for LAL deficiency treatment market. The Europe commission in 2015
granted marketing permission of Kanuma, for the treatment of LAL deficiency for patients of all
ages, which is expected to fuel the growth of kanuma in region.
Get Exclusive Discount on this CMI Report:
https://www.coherentmarketinsights.com/insight/request-discount/904
Rapid approval of therapy by FDA in various region, be an opportunities for companies
Ltd. In 2015, FDA approved Kanuma, an innovative enzyme replacement therapy (ERT) in the
U.S., Europe Union, and Japan, which is providing an opportunity to manufacturers for
exploring their business in the untapped market. Major players operating in global Lysosomal
Acid Lipase (LAL) Deficiency treatment market include Alexion Pharmaceutical Inc., Merck &
Co., Inc., Pfizer, Inc., and AstraZeneca plc. and Teva Pharmaceutical Industries.
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS
ABOUT US
Coherent Market Insights is a global market intelligence and consulting organization focused on
assisting its plethora of clients achieve transformational growth by helping them make critical business
decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our
client base includes players from across all business verticals in over 150 countries worldwide. We are
uniquely positioned to help businesses around the globe deliver practical and lasting results through
various recommendations about operational improvements, technologies, emerging market trends and
new working methods. We offer both customized and syndicated market research reports that help our
clients create visionary growth plans to provide traction to their business. We meticulously study
emerging trends across various industries at both the global and regional levels to identify new
opportunities for our clientele.
SERVICES
INDUSTRY ANALYSIS
CUSTOMIZED
RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE
SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC
STUDIES
© Coherent market Insights. All Rights Reserved
ABOUT CMI
SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
 Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry
 Component Providers and System Integrators
 Private and Government organization
 Distributors, Retailors and Value Added Resellers
 Outsourcing Companies
 Healthcare IT Solutions Developers
 Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY
STUDIES
Insights Published
Per Year
GLOBAL
REPORTS
150+
Consulting Projects
Till Date
COUNTRY
ANALYSIS
CONSULT
PROJECTS
125+
Clients Worldwide
Per Year
110+
SURVEY
RESEARCH
EXCEL
FORECAST
DATABASE
CUSTOMIZED
SOLUTIONS
COMPETITIVE
ASSESSMENT
TECHNOLOGY
SNIPPETS
Analysts and Contract
Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals,
including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in
order to result in the best possible market research reports across various industries worldwide. Based on our unmatched
expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better
outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure
sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of
opportunities posed therein.
© Coherent market Insights. All Rights Reserved
THANK YOU
To know more about us, visit our website:
www.coherentmarketinsights.com
For sales queries or new topics email us on:
[email protected]
For other queries contact:
Mr. Shah
(Manager - Business Development)
Coherent Market Insights
[email protected]
+1-206-701-6702
© Coherent market Insights. All Rights Reserved
Author
Albert Rock
Albert Rock157   documents Email
Document
Category
Uncategorized
Views
3
File Size
717 KB
Tags
deficiency
1/--pages
Report inappropriate content